Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebivolol vs Metoprolol Effects on Blood Flow in Hypertension
NCT01502787Phase 4
Key facts
- Status
- Completed
- Start
- Apr 2009
- Primary completion
- Jun 2013
- Countries
- 1
- Sponsor
- UT Southwestern Medical Center
- Modality
- Small Molecules
- Drugs
- nebivolol
- Conditions
- hypertension (HTN)
01
Overview
Phase 4, randomised, double-blind trial of nebivolol in hypertension (HTN) (2 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: Forearm Blood Flow at 12 weeks. Started Apr 2009; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Metoprolol First
Metoprolol succinate (100-300 mg/day) for 12 weeks, then washout, then Nebivolol (5-20 mg/day) for 12 weeks.
Nebivolol First
Nebivolol (5-20 mg/day) for 12 weeks, then washout, then Metoprolol succinate (100-300 mg/day) for 12 weeks.
03
Who it enrols
Adults aged 18-65 with Stage I hypertension (140-159/90-99 mmHg), excluding those with CHF, CAD, asthma, COPD, or creatinine > 1.4 mg/dL.
04
Endpoints
Primary
Forearm Blood Flow
Secondary
Blood Pressure During Exercise
Blood Pressure During Angiotensin II Infusion
Beyond the preview
Go deeper on NCT01502787.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01502787.